Cognition and communication dysfunctions in early-onset schizophrenia: Effect of risperidone

Remberk, Barbara; Namysłowska, Irena; Rybakowski, Filip

doi:10.1016/j.pnpbp.2012.07.007

Cited by 16 publications

(12 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Antipsychotic drugs, such as risperidone and olanzapine, are known to show limited efficacy in cognitive impairment, including social recognition in schizophrenia and depression (Sergi et al, 2007;Krakowski and Czobor, 2011;Suzuki et al, 2011;Remberk et al, 2012), despite improving various cognitive functions in rodent disease models (Wang et al, 2007;Gumuslu et al, 2013;Mutlu et al, 2011Mutlu et al, , 2012Wolff and Leander, 2003). It is of considerable clinical importance to find new ways of improving social recognition deficits in patients with psychiatric diseases, such as schizophrenia and MDD, because of their huge negative impact on the social functioning of patients (Tandberg et al, 2011;Tse et al, 2013;Horan et al, 2012).…”

Section: Discussionmentioning

confidence: 99%

Improvement of dizocilpine-induced social recognition deficits in mice by brexpiprazole, a novel serotonin–dopamine activity modulator

Yoshimi¹,

Futamura²,

Hashimoto³

2015

European Neuropsychopharmacology

View full text Add to dashboard Cite

Cognitive impairment, including impaired social cognition, is largely responsible for the deterioration in social life suffered by patients with psychiatric disorders, such as schizophrenia and major depressive disorder (MDD). Brexpiprazole (7-{4-[4-(1-benzothiophen-4-yl)piperazin-1-yl]butoxy}quinolin-2(1H)-one), a novel serotonin-dopamine activity modulator, was developed to offer efficacious and tolerable therapy for different psychiatric disorders, including schizophrenia and adjunctive treatment of MDD. In this study, we investigated whether brexpiprazole could improve social recognition deficits (one of social cognition deficits) in mice, after administration of the N-methyl-d-aspartate (NMDA) receptor antagonist MK-801 (dizocilpine). Dosing with dizocilpine (0.1mg/kg) induced significant impairment of social recognition in mice. Brexpiprazole (0.01, 0.03, 0.1mg/kg, p.o.) significantly ameliorated dizocilpine-induced social recognition deficits, without sedation or a reduction of exploratory behavior. In addition, brexpiprazole alone had no effect on social recognition in untreated control mice. By contrast, neither risperidone (0.03mg/kg, p.o.) nor olanzapine (0.03mg/kg, p.o.) altered dizocilpine-induced social recognition deficits. Finally, the effect of brexpiprazole on dizocilpine-induced social recognition deficits was antagonized by WAY-100,635, a selective serotonin 5-HT1A antagonist. These results suggest that brexpiprazole could improve dizocilpine-induced social recognition deficits via 5-HT1A receptor activation in mice. Therefore, brexpiprazole may confer a beneficial effect on social cognition deficits in patients with psychiatric disorders.

show abstract

Section: Discussionmentioning

confidence: 99%

Improvement of dizocilpine-induced social recognition deficits in mice by brexpiprazole, a novel serotonin–dopamine activity modulator

Yoshimi¹,

Futamura²,

Hashimoto³

2015

European Neuropsychopharmacology

View full text Add to dashboard Cite

show abstract

“…This may also mean better compliance. We cannot exclude that therapeutic interventions including pharmacotherapy may have an impact on the improvement of prognosis and outcome, despite doubtful evidence for the direct effect of antipsychotic treatment on executive functioning [23,33]. …”

Section: Discussionmentioning

confidence: 99%

“…The baseline WCST assessment took place during the early stage of acute psychotic episode, i.e.before or within the first week after the introduction of the new antipsychotic treatment. The WCST assessment took place either as a part of another study procedure [23] or due to the clinical need of executive function assessment. None of the patients had been rejected from the assessment due to illness severity or any other reason.…”

Section: Methodsmentioning

confidence: 99%

Executive Impairment Predicts Schizophrenia Diagnosis and Treatment Status in Mid-Term Follow-Up of Early-Onset Psychosis

et al. 2014

Self Cite

View full text Add to dashboard Cite

Objectives: Early-onset psychoses (EOP) vary considerably with regard to diagnostic stability and functional outcome. The aim of this study was the assessment of executive dysfunction as a predictor of outcome in EOP. Method: This was a retrospective cohort study. Twenty-five hospitalized patients with non-affective EOP were assessed with the Wisconsin Card Sorting Test (WCST) during the index admission. Associations with current diagnosis, further admissions, current treatment status and occupational and relationship outcome were analyzed in 6 years of follow-up. Results: The mean age at the index admission and the follow-up was 16.1 ± 1.35 and 22.0 ± 2.1 years, respectively. After discharge, almost all subjects (96%) at least briefly continued psychiatric treatment, and the majority of them (76%) were readmitted. Worse baseline WCST results were associated with a follow-up schizophrenia diagnosis, being a psychiatric in- or outpatient at the moment of follow-up assessment and receiving psychotropic medication. A low number of completed categories correlated with receiving a disability pension at the follow-up. Conclusion: In patients with EOP, baseline executive function impairment was associated with schizophrenia diagnosis and psychiatric treatment at the follow-up. The association between baseline results and psychiatric treatment may explain the limited effect of baseline impairment on follow-up occupational and relationship status.

show abstract

“…Thought disorder predicted psychosis transition of young people at-risk mental state (Katsura et al, 2014) and was also found among relatives of patients with schizophrenia (Manschreck et al, 2012). It is moderately stable (trait marker; Wilcox et al, 2012) but becomes exacerbated during the acute episode, tends to increase in severity with illness duration (Maeda et al, 2007), and may also persist during antipsychotic treatment (Remberk et al, 2012). Thought disorder can be as disabling as the other symptoms of schizophrenia, limiting social and occupational functioning (Tirupati et al, 2004) as well as wellbeing and life satisfaction (Sigaudo et al, 2014;Tan et al, 2014).…”

Section: Introductionmentioning

confidence: 93%

The impact of thought disorder on therapeutic alliance and personal recovery in schizophrenia and schizoaffective disorder: An exploratory study

Cavelti

Homan

Vauth³

2016

Psychiatry Research

View full text Add to dashboard Cite

Cognition and communication dysfunctions in early-onset schizophrenia: Effect of risperidone

Cited by 16 publications

References 54 publications

Improvement of dizocilpine-induced social recognition deficits in mice by brexpiprazole, a novel serotonin–dopamine activity modulator

Improvement of dizocilpine-induced social recognition deficits in mice by brexpiprazole, a novel serotonin–dopamine activity modulator

Executive Impairment Predicts Schizophrenia Diagnosis and Treatment Status in Mid-Term Follow-Up of Early-Onset Psychosis

The impact of thought disorder on therapeutic alliance and personal recovery in schizophrenia and schizoaffective disorder: An exploratory study

Contact Info

Product

Resources

About